Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
3
institutions
Market cap
$158.0B
5,700M shares
52-week range
$23.58 – $29.21
72% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NYSE
CS
P/S (TTM)
2.5
EV / FCF (TTM)
20.0
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndamax and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
www.pfizer.comNo one on the platform currently holds PFE.
| Institution | Shares | Reported |
|---|---|---|
| Scion Asset ManagementCALLas of 2025-09-30 | 6,000,000 | $152.9M |
| Renaissance Technologiesas of 2025-09-30 | 3,395,558 | $86.5M |
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-07-24 | $0.4300 | 2026-09-01 |
| 2026-05-08 | $0.4300 | 2026-06-12 |
| 2026-01-23 | $0.4300 | 2026-03-06 |
| 2025-11-07 | $0.4300 | 2025-12-01 |
| 2025-07-25 | $0.4300 | 2025-09-02 |
| 2025-05-09 | $0.4300 | 2025-06-13 |
| 2025-01-24 | $0.4300 | 2025-03-07 |
| 2024-11-08 | $0.4200 | 2024-12-02 |
| 2024-07-26 | $0.4200 | 2024-09-03 |
| 2024-05-09 | $0.4200 | 2024-06-14 |
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 10.5% | 14.3% | 13.5% | — | — | — |
| Rev. Growth % | -1.6% | 8.5% | ||||
| Profit Margin % | 12.4% | 17.4% | 22.4% | |||
| Free Cash Flow Margin % | 14.5% | 20.1% | 23.2% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is -1.2% on the P/E track.
At today's price, your expected annual return is +2.5% on the P/E track.
At today's price, your expected annual return is +6.1% on the P/E track.
| 1,012,754 |
| $24.5M |
| 2024-01-25 | $0.4200 | 2024-03-01 |
| 2023-11-09 | $0.4100 | 2023-12-04 |
Also held through funds
2 more books hold PFE indirectly · VTI 0.2% of fund
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $62.2B | +0.5% | $2.97 | $2.87–$3.09 | 9.3× | 14 |
| 2027 | $59.8B | -4.0% | $2.90 | $2.77–$3.10 | 9.5× | 14 |
| 2028 | $54.8B | -8.3% | $2.49 | $1.60–$3.01 | 11.1× | 8 |
| 2029 | $52.9B | -3.5% | $2.36 | $2.27–$2.46 | 11.7× | 5 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 8 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-04 | $0.68 | $0.77 | +12.9% |
| 2026-05-05 | $0.72 | $0.75 | +3.9% |
| 2026-02-03 | $0.57 | $0.66 | +16.4% |
| 2025-11-04 | $0.63 | $0.87 | +37.4% |
| 2025-08-05 | $0.58 | $0.78 | +34.5% |
| 2025-04-29 | $0.67 | $0.92 | +38.1% |
| 2025-02-04 | $0.47 | $0.63 | +33.6% |
| 2024-10-29 | $0.61 |
| $1.06 |
| +72.6% |
| $142.9B |
| — |
| GILDGilead Sciences, Inc. | $146.41 | +1.87% | $181.8B | — |
| GSKGSK plc | $50.05 | +4.00% | $100.3B | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
Can Viking Therapeutics Beat Big Pharma With Monthly Weight-Loss Shots? Here’s The Risk CEO Says Could Derail It $VKTX $NVO $LLY $PFE https://stocktwits.com/news/equity/markets/viking-therapeutics-big-pharma-monthly-weight-loss-shots-risk-ceo-derail/cZtnGIiRBTV
View on StockTwits ↗
$CRDF mPFS is up next, followed by an offer from $PFE for $1.2 Billion, which Cardiff will accept - it's a done deal. Pace isn't going to let them go it alone and chase a P3, that's never successful. Sell it at a discount is what will happen. Glad to see today's settlement. I will be adding more shares tomorrow.
View on StockTwits ↗
$PFE Share Price: $27.74 Contract Selected: Oct 09, 2026 $30 Calls Buy Zone: $0.03 – $0.03 Target Zone: $0.05 – $0.06 Potential Upside: 79% ROI Time to Expiration: 24 Days | Updates via https://fxcapta.com/stockinfo/
View on StockTwits ↗
$PFE they will keep this below $28 all week so that my 1000s of calls expire worthless, sorry team
View on StockTwits ↗
@Outcomes $MRNA $PFE $JNJ $IBRX Just hope that RNA messenger are not trigging something else... like cancers !! Because the vaccine was done very fast...during Covid !!
View on StockTwits ↗
$SLS $JNJ$AZN $PFE Only☝️ Thing that requires this kind of 🤐 at this point is an outright BO! ✌️🙏❤️🩹
View on StockTwits ↗
The zionist's were covering up COVID vaccines deaths also $MRNA $PFE $BNTX https://www.instagram.com/reel/DdReFG2xP_B/?stkn=ZmRlMnU4bGRwb2gz
View on StockTwits ↗
$PFE reminds me of old days .. when market red , this would rippp ..
View on StockTwits ↗
$PFE Dividend Payout is @ 126.85% according to Finviz ?? What's next ??
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.